FCGR3A and cancer: Similarly, previously described TriKE constructs (TriKE 161533, and TriKE 1615133) (273), which incorporate an IL-15 linker and contain anti-CD16 and anti-CD33 fragments (161533 TriKE), or anti-CD16 and anti CD133 fragments (1615133 TriKE), were described for activating NK cells against neoplastic mast cells, myelodysplastic syndrome cells, and cancer stem cells (273–275), as well as providing NK cells with sustained survival and proliferation signals.